The Effect of Voxelotor on Cerebral Hemodynamic Response in Children With Sickle Cell Anemia

Summary

Voxelotor is a new drug for adolescents and adults with sickle cell disease that improves hemoglobin levels and reduces the incidence of worsening anemia. However, it is unclear whether this increase in hemoglobin is associated with a reduction in cerebral metabolic stress. This study will measure the effects of voxelotor on cerebral hemodynamics.

Timeline

Start

2022-03-28

Primary completion

2024-10-22

Completion

2024-10-22

Outcome

Outcome not reported

Stopped: “This study was terminated on September 26, 2024 due to voluntary withdrawal of study drug from the market.”

Publications

• Brothers RO, Turrentine KB, Akbar M, Triplett S, Zhao H, Urner TM, Goldman-Yassen A, Jones RA, Knight-Scott J, Milla SS, Bai S, Tang A, Brown RC, Buckley EM. The influence of voxelotor on cerebral blood flow and oxygen extraction in pediatric sickle cell disease. Blood. 2024 May 23;143(21):2145-2151. doi: 10.1182/blood.2023022011.

Drugs

Indications